Interleukin-22: A likely target for treatment of autoimmune diseases

Yang, Xuyan; Zheng, Song Guo

doi:10.1016/j.autrev.2013.11.008

Cited by 89 publications

(79 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent an experimental study has been shown that synovial inflammation was not affected in IL-22-/-mice and this study concludes that the local IL-22 produced by adaptive or innate immune cell have no direct contribution to the induction of T cell-mediated synovial inflammation 29 . Many studies suggest that the possible explanation for these differences is depending on different phases of the disease development 29,30,41 .…”

Section: Resultsmentioning

confidence: 99%

Interleukin-22 Serum Levels in Patients With Rheumatoid Arthritis in Sana'a City, Yemen

El-Aghbary

Darwiesh

Al-Moyed

2018

UJPR

View full text Add to dashboard Cite

Interleukin (IL) -22 is a novel mediator of a member of IL-10 family cytokines that is produced by many different types of lymphocytes including both those of innate and adaptive immune system. This cytokine has potent proliferative and inflammatory effects on different cell lines. Recently, accumulated data has indicated that IL-22 plays an important role in the pathogenesis of rheumatoid arthritis (RA). We aimed to investigate the levels of IL-22 and its association with demographic, clinical data as well as serological markers in RA. IL-22 serum levels were measured in 45 newly diagnosed RA patients without any treatment and 45 healthy individuals as control by a manual Enzyme linked immunosorbent assay (ELISA). Correlations of IL-22 serum levels were sought with demographic, clinical data and serological parameters. IL-22 levels were significantly elevated in serum of RA patients (median= 86.89ng/ml and range = 896) compared to serum of healthy control (median=75.36ng/ml and range=459), p=.022. The IL-22 levels were correlated positively with C-reactive protein (CRP), anti-cyclic citrullinated peptide (ACCP) antibodies in RA patients. Significant higher levels of serum IL-22 in RA patients compare with those in healthy control. Highly significant association between serum levels of IL-22 and the serological markers (CRP and ACCP antibodies) in the diagnosis of RA suggest the potential levels of IL-22 as a valuable biomarker for the evaluation of disease severity in RA patients. Keywords: Anti-cyclic citrullinated peptide antibody, C-reactive protein, Interleukin-22, rheumatoid arthritis, rheumatoid factor.

show abstract

Section: Resultsmentioning

confidence: 99%

Interleukin-22 Serum Levels in Patients With Rheumatoid Arthritis in Sana'a City, Yemen

El-Aghbary

Darwiesh

Al-Moyed

2018

UJPR

View full text Add to dashboard Cite

show abstract

“…Increased levels of IL-22 were found to be associated with lupus erythematosus (Zhao et al, 2013b), Sjogren's syndrome (Ciccia et al, 2012), Behcet's disease (Cai et al, 2013), asthma (Pennino et al, 2013;Manni et al, 2014), atopic dermatitis (Nograles et al, 2009), multiple sclerosis (Beyeen et al, 2010), psoriasis (Ouyang, 2010;Hao, 2013), inflammatory bowel disease (ibd) (Seiderer and Brand, 2009;Ouyang, 2010), and rheumatoid arthritis (da Rocha, 2012;Xie et al, 2012). It is interesting, however, that multiple experiments on animal models showed that IL-22 may exert either a pathogenic impact or a protective impact on the above-mentioned diseases (Yang and Zheng, 2014). In particular, two different groups independently observed that IL-22 is a survival factor for hepatocytes during acute liver inflammation (Radaeva et al, 2004;Zenewicz et al, 2007).…”

Section: Overviewmentioning

confidence: 94%

Interleukin-10 Superfamily and Cancer

Yuzhalin¹,

Kutikhin²

2015

Interleukins in Cancer Biology

View full text Add to dashboard Cite

“…Interleukin-22 functions in synergy with for example IL-17 but also with TNF-α and IFN-γ [24] . T-helper 22 cells differentiate in response to TNF-α and IL-6 [23] and effects via the IL-22-IL22R complex [25] . These Th22 cells are suggested to play for example an important role in autoimmune diseases like graft versus host disease, rheumatoid arthritis, hepatitis and psoriasis [25] as well as in allergy and epidermial immunity and remodeling [26] .…”

Section: T-helper 2 Cells Require the Transcription Factors Stat6mentioning

confidence: 99%

Children diagnosed with both Type 1 diabetes and Celiac disease - An Immunological challenge

Faresjö

2016

Immunoendocrinology

View full text Add to dashboard Cite

Type 1 diabetes (T1D) and celiac disease are both characterized by an autoimmune feature. As T1D and celiac disease share several common risk factors such as environment, genetics and immune dysregulation, patients have risk of developing the other disease subsequently. Patients with manifest T1D may have had a latent celiac disease, which is activated parallel to the anti-islet immune reactivity during the development of T1D. Contrary, a low prevalence of β-cell autoimmunity is found in young patients with celiac disease. The role of antigen-specific T cells and their relation to cytokines and chemokines is not well characterized in children with combination of T1D and celiac disease. Defective regulation and an impaired ability of responder T cells to be suppressed are suggested to contribute. We have previously shown that children suffering from these two immunological diseases in combination have a suppressed immune response to several antigens for example food antigens like gluten. Poor development of oral tolerance seen as immune aberrancies with low percentages of both early and late effector memory CD8 + cells in the gut of children who are prone to T1D may predispose for development of celiac disease. This review highlights the immunological complexity in these two common pediatric immunological disorders that indicates that the combination of type 1 diabetes and celiac disease is an immunological challenge. It is obvious that we are far from understanding the immunological impact of these two autoimmune diseases in combination. This immunological challenge therefore needs to be elucidated to be able to predict and prevent these autoimmune diseases.

show abstract

Interleukin-22: A likely target for treatment of autoimmune diseases

Cited by 89 publications

References 51 publications

Interleukin-22 Serum Levels in Patients With Rheumatoid Arthritis in Sana'a City, Yemen

Interleukin-22 Serum Levels in Patients With Rheumatoid Arthritis in Sana'a City, Yemen

Interleukin-10 Superfamily and Cancer

Children diagnosed with both Type 1 diabetes and Celiac disease - An Immunological challenge

Contact Info

Product

Resources

About